<SEC-DOCUMENT>0001171843-20-005566.txt : 20200805
<SEC-HEADER>0001171843-20-005566.hdr.sgml : 20200805
<ACCEPTANCE-DATETIME>20200805170403
ACCESSION NUMBER:		0001171843-20-005566
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200805
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200805
DATE AS OF CHANGE:		20200805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		201078455

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_080520.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title></title></head><body><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;"><font style="font-size: 10pt;">&#160;</font></div></div><p style="text-align: center;"><font style="font-size: 14pt;"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong><br />_____________________</font></p><p style="text-transform: uppercase; text-align: center;"><font style="font-size: 14pt;"><strong>Form 8-K</strong><br />_____________________</font></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>CURRENT REPORT</strong></font></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</strong></font></p><p align="center"><font style="font-size: 10pt;">Date of Report (Date of earliest event Reported): <!--August 5, 2020-->August 5, 2020 &#160;</font></p><p align="center"><font style="font-size: 12pt;"><strong>Anika Therapeutics, Inc.</strong></font><br /><font style="font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td align="center" width="33%"><font style="font-size: 10pt;"><strong>Delaware</strong></font></td><td align="center" width="34%"><font style="font-size: 10pt;"><strong>000-21326</strong></font></td><td align="center" width="33%"><font style="font-size: 10pt;"><strong>04-3145961</strong></font></td></tr><tr valign="top"><td align="center" width="33%"><font style="font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</font></td><td align="center" width="34%"><font style="font-size: 10pt;">(Commission File Number)</font></td><td align="center" width="33%"><font style="font-size: 10pt;">(I.R.S. Employer Identification Number)</font></td></tr></table><p><font style="font-size: 10pt;">&#160;</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="bottom"><td align="center" width="50%"><font style="font-size: 10pt;"><strong>32 Wiggins Avenue, Bedford, Massachusetts 01730</strong><!----></font></td></tr><tr valign="top"><td align="center" width="50%"><font style="font-size: 10pt;">(Address of Principal Executive Offices) (Zip Code)</font></td></tr></table><p align="center"><font style="font-size: 10pt;"><strong>(781) 457-9000</strong><br />(Registrant's telephone number, including area code)</font></p><p align="center"><font style="font-size: 10pt;"><strong>Not Applicable</strong><br />(Former name or former address, if changed since last report)</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td colspan="3"><font style="font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br /><br /></font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; margin: 0pt 0px;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-size: 10pt; margin: 0pt;">&#160;</p><table style="width: 100%; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 40%; border: 1pt solid black; text-align: center;"><font>Title of each class</font></td><td style="width: 20%; border-top: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; text-align: center;"><font>Trading Symbol(s)</font></td><td style="width: 40%; border-top: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; text-align: center;"><font>Name of each exchange on which registered</font></td></tr><tr style="vertical-align: top;"><td style="border-right: 1pt solid black; border-bottom: 1pt solid black; border-left: 1pt solid black; text-align: center;"><font>Common Stock, par value $0.01 per share</font></td><td style="border-right: 1pt solid black; border-bottom: 1pt solid black; text-align: center;"><font>ANIK</font></td><td style="border-right: 1pt solid black; border-bottom: 1pt solid black; text-align: center;"><font>NASDAQ Global Select Market</font></td></tr></table><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-size: 10pt; margin: 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company [&#160;&#160; ]</p><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-size: 10pt; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160; ]</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">&#160;</p><div style="margin-top: 12pt; margin-bottom: 3pt;"><div style="font-size: 1pt; border-top: Black 1.1pt solid; border-bottom: Black 2.5pt solid; width: 100%;"><font style="font-size: 10pt;">&#160;</font></div>&#160;</div><hr style="page-break-after: always;" noshade="noshade" /><p><font style="font-size: 10pt;">  <strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</strong></font></p><p><font style="font-size: 10pt;"><p style="margin-left: 0in; margin-right: 0in;" align="justify"><font style="color: black; font-size: 10pt; font-family: 'Times New Roman';">On August 5, 2020, we announced that the board of directors has appointed Michael Levitz as our Executive Vice President, Chief Financial Officer and Treasurer, effective August&#160;10, 2020. </font></p><p style="margin-left: 0in; margin-right: 0in;" align="justify"><em><font style="color: black; font-size: 10pt; font-family: 'Times New Roman';">Offer Letter with Michael Levitz</font></em></p><p style="margin-left: 0.25in; margin-right: 0in;" align="justify"><font style="color: black; font-size: 10pt; font-family: 'Times New Roman';">Pursuant to an offer letter dated July 29, 2020, we have agreed Mr. Levitz will receive an annual base salary of $450,000 and will be eligible to receive a discretionary annual cash bonus with a target bonus of 45% of his base salary (prorated for 2020). Upon the commencement of his employment, Mr. Levitz will be granted an equity package consisting of:</font></p><ul><li><font style="color: black; font-size: 10pt; font-family: 'Times New Roman';">restricted stock units with a fair market value of $400,000 as of August 10, 2020, which will vest in three equal annual installments beginning one year from the date of grant;</font></li><li><font style="color: black; font-size: 10pt; font-family: 'Times New Roman';">performance stock units with a fair market value at target (<em>i.e.</em>, 100% achievement of the performance metrics) of $400,000 as of August 10, 2020, which will vest when and to the extent certain performance criteria (standardized across our executive team) are met as measured by the board&rsquo;s compensation committee following the audit of our financial statements for fiscal year 2022;</font></li><li><font style="color: black; font-size: 10pt; font-family: 'Times New Roman';">common stock options with a fair market (<em>i.e.</em>, Black-Scholes) value of $800,000 as of August 10, 2020, which will vest in three equal annual installments beginning one year from the date of grant.</font></li></ul><p style="margin-left: 0.25in; margin-right: 0in;" align="justify"><em><font style="color: black; font-size: 10pt; font-family: 'Times New Roman';">The foregoing description of our offer letter with Mr. Levitz does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the offer letter, which is included as Exhibit 10.1 to this report and is incorporated into this Item 5.02 by reference.</font></em></p><p style="margin-left: 0in; margin-right: 0in;" align="justify"><em><font style="color: black; font-size: 10pt; font-family: 'Times New Roman';">Background of Michael Levitz</font></em></p><p style="margin-left: 0.25in; margin-right: 0in;" align="justify"><font style="color: black; font-size: 10pt; font-family: 'Times New Roman';">Mr. Levitz served as the Senior Vice President, Chief Financial Officer and Treasurer of Insulet Corporation, a global medical device and drug delivery company, from May 2015 to January 2019. From 2009 to May 2015, Mr. Levitz was the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation, a global provider of medical guidance, diagnostic imaging and threat detection equipment. Previously, during his seven years with Hologic, Inc. and Cytyc Corporation (which merged with Hologic in October 2007), Mr. Levitz s</font><font style="font-size: 10pt; font-family: 'Times New Roman';">erved in various capacities including Vice President and Corporate Controller. Mr. Levitz began his career in the high technology audit practice at Arthur Andersen LLP. Mr. Levitz earned his Bachelor of Arts in Business Economics, with emphasis in Accounting, from the University of California Santa Barbara and is a certified public accountant. He is 47 years old.</font></p><p style="margin-left: 0.25in; margin-right: 0in;" align="justify"><font style="font-size: 10pt; font-family: 'Times New Roman';">There are no relationships or related party transactions involving Mr. Levitz or any member of his immediate family required to be disclosed pursuant to Item 404(a) of Regulation S-K.</font></p><p style="margin-left: 0in; margin-right: 0in;" align="justify"><em><font style="color: black; font-family: 'Times New Roman';">Transition Arrangements with Sylvia Cheung</font></em></p><p style="margin-left: 0.25in; margin-right: 0in;" align="justify"><font style="color: black; font-family: 'Times New Roman';">Mr. Levitz succeeds Sylvia Cheung as our Chief Financial Officer and Treasurer. As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 2, 2020, Ms. Cheung notified us on May&#160;27, 2020 that she was resigning from her position of Chief Financial Officer, Treasurer and Assistant Secretary effective August 21, 2020 for personal reasons. Ms. Cheung has advised us that she will continue with the Company in an advisory capacity for a period following the succession effective date to assist with a smooth transition.</font></p></font></p><p><font style="font-size: 10pt;"><strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 7.01. Regulation FD Disclosure.</strong></font></p><p><font style="font-size: 10pt;">
 <p style="margin-left:0in; margin-right:0in;"><font style="color:black; font-size:10pt; font-family:'Times New Roman';">On August 5, 2020, we issued a press release entitled &#8220;Anika Appoints Michael Levitz as Chief Financial Officer.&#8221; A copy of the press release is furnished as Exhibit 99.1 to this report.</font></p>   <p align="justify" style="margin-left:0in; margin-right:0in;"><em><font style="color:black; font-size:10pt; font-family:'Times New Roman';">The information contained in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this report shall not be incorporated by reference into any of our filings with the Securities and Exchange Commission, whether made before, on or after the date of this report, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. The information contained in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this report shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section or Section 11 or 12(a)(2) of the Securities Act of 1933.</font></em></p> </font></p><p><font style="font-size: 10pt;"><strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 9.01. Financial Statements and Exhibits.</strong></font></p><p><font style="font-size: 10pt;"><p style="margin-left: 0in; margin-right: 0in;"><strong><em><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)&#160;&#160; Exhibits.</font></em></strong></p><table style="margin-left: 0.25in; width: 96.16%; border-collapse: collapse !important; ;border-collapse: collapse;"><tr><td style="border-bottom: solid black 1pt; text-align: center; vertical-align: middle;"><strong><font style="font-size: 8pt; font-family: 'Times New Roman';">Exhibit Number</font></strong></td><td class="hugin"><font style="font-size: 8pt; font-family: 'Times New Roman';">&#160;</font></td><td style="border-bottom: solid black 1pt; text-align: center; vertical-align: bottom;"><strong><font style="font-size: 8pt; font-family: 'Times New Roman';">Description</font></strong></td><td class="hugin"><font style="font-size: 8pt; font-family: 'Times New Roman';">&#160;</font></td></tr><tr><td style="text-align: center; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><a href="exh_101.htm">10.1</a></font></td><td class="hugin"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</font></td><td class="hugin"><font><a href="exh_101.htm"><font style="font-size: 10pt; font-family: 'Times New Roman';">Offer letter dated as of July 29, 2020 between Anika Therapeutics, Inc. and Michael Levitz</font></a></font></td><td class="hugin"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</font></td></tr><tr><td style="text-align: center; vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_991.htm" rel="nofollow">99.1</a></font></td><td class="hugin"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</font></td><td class="hugin"><font style="font-size: 10pt;"><a href="exh_991.htm" rel="nofollow"> Press release dated August 5, 2020 </a></font></td><td class="hugin"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</font></td></tr></table></font></p><p><font style="font-size: 10pt;"></font></p><p><font style="font-size: 10pt;"></font></p><hr style="page-break-after: always;" noshade="noshade" /><p align="center"><font style="font-size: 10pt;"><strong>SIGNATURE</strong></font></p><p><font style="font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td valign="top" width="49%"><font style="font-size: 10pt;">&#160;</font></td><td style="font-size: 12pt;" colspan="2" valign="top"><font style="font-size: 10pt;"><strong>Anika Therapeutics, Inc.</strong></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">&#160;</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;"></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">Date: August 5, 2020</font></td><td width="2%"><font style="font-size: 10pt;">By:&#160;</font></td><td style="text-decoration: underline;" width="49%"><font style="font-size: 10pt;">/s/ CHERYL R. BLANCHARD&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">President and Chief Executive Officer<!--CHERYL R. BLANCHARD--></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%">&#160;</td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;"></font></td></tr></table><p /></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh_101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html lang="en-US"><head><title>EdgarFiling</title>
<meta content="text/html; charset=windows-1252" >
<meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head>
<body>
<p ></p>

<p style="text-align: right; margin: 0"><b>Exhibit 10.1</b></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><img src="logo.jpg" alt="" style="height: 39; width: 200" >&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0" ></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 29, 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael Levitz</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Michael:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2F2F2F">I am pleased to confirm our offer to you
to join Anika Therapeutics, Inc. (&ldquo;Anika&rdquo; or the <font style="color: #464646">&ldquo;Company&rdquo;)</font><font style="color: #2F2F2F">.
We are excited about the prospect of having you join our team and look forward to the addition of your professionalism and
experience to help the Company achieve its goals. This letter summarizes the initial terms of our offer for your employment
with the Company. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2F2F2F">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2F2F2F"><u>Starting Position</u>: Executive Vice President,
Chief Financial Officer (CFO) and Treasurer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25pt"><font style="color: #2F2F2F"><u>Description
of Duties</u>: You will serve as a key member of the corporate leadership team. </font>Your initial duties will include those intrinsic
to your position, as described in the job description being provided to you with this offer letter and such other duties, reasonably
consistent with your position, as may be assigned to you from time to time. <font style="color: #2F2F2F">Your initial responsibilities
will include providing leadership to all aspects of Anika&rsquo;s financial processes. Also, you shall be responsible for performing
any duties assigned to you by or under the authority of the Company that are appropriate for an individual of your experience.</font>
You will be expected to devote your full business time and your best professional efforts to the performance of your duties and
responsibilities for the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2F2F2F"><u>Reporting To</u>: Cheryl Blanchard, President
and Chief Executive Officer, Anika Therapeutics, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2F2F2F">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2F2F2F"><u>Employment Date</u>: We anticipate that you
will begin your at-will employment with Anika on August 10<sup>th</sup>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2F2F2F">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="color: #2F2F2F"><u>Initial Rate of Pay</u>: $17,307.70
per bi-weekly payroll (annualized $450,000.00). </font>You will be paid in accordance with the Company&rsquo;s normal payroll practices
as established or modified from time to time, and your compensation shall be subject to all applicable federal, state and local
taxes and withholdings. Currently, <font style="color: #2F2F2F">paychecks are issued on alternating Fridays.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Bonus Eligibility</u>: You will be eligible to receive a
discretionary annual cash bonus. Your initial annual target bonus is 45% of your annualized base salary, subject to all applicable
taxes and withholdings. Your eligibility for this bonus shall be subject to determination by the Board of Directors and based on
the Company's performance and your personal performance against key objectives. Any bonus payout which may be made for 2020 will
be prorated based on your length of service in 2020. Your actual bonus payout may be adjusted depending on your and the Company&rsquo;s
performance, at the sole discretion of the Company&rsquo;s Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Equity Grants</u>: Subject to the approval of the Compensation
Committee of the Board of Directors of the Company, you will be granted an equity package as of the date of the commencement of
your employment (with agreements to entered shortly thereafter). The equity package will consist of (a) restricted stock units
with a fair market value of $400,000 as of the date of grant, (b) performance stock units with a fair market value at target (i.e.,
100% achievement of the performance metrics) of $400,000 as of the date of grant, and (c) common stock options with a fair market
value (i.e., Black-Scholes value) of $800,000 as of the date of grant. The restricted stock units represent a contingent right
to receive shares of Anika&rsquo;s common stock at annual intervals throughout your employment with the Company, and the performance
stock units represent a contingent right to receive shares of Anika common stock should certain performance criteria (standardized
across the Anika executive team) be met. The restricted stock units will vest ratably over three years beginning one year from
the date of hire and the performance stock units will vest when and to the extent measured by the Compensation Committee of the
Board of Directors following the audit of fiscal year 2022 in early 2023. Each will be granted under, and governed by, the Anika
Therapeutics, Inc. 2017 Omnibus Incentive Plan, and any applicable grant instruments. Continued employment with the Company is
a condition precedent to the vesting of either the restricted stock units or performance stock units. The common stock options
<font style="color: #2F2F2F">shall be considered &ldquo;Incentive Stock Options&rdquo; to the extent permissible under Section
422 of the Internal Revenue Code. The stock options represent a contingent right to purchase shares of Anika&rsquo;s common stock
at an exercise price equal to the stock&rsquo;s closing price on the date of the grant. The options will vest ratably over three
years beginning one year from the date of hire, and they will be granted under, and governed by, the Anika Therapeutics, Inc. 2017
Omnibus Incentive Plan, and any applicable grant instruments. Continued employment with the Company is a condition precedent to
the vesting of any incentive stock options.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0" ></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 50%"><p style="color: #19559A; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">ANIKA
                           THERAPEUTICS, INC.</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">32 Wiggins Avenue</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Bedford, MA 01730</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">anikatherapeutics.com</font></p>


</td>
    <td style="width: 50%"><p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">&#160;</font></p>
                           <p style="font: 10pt Times New Roman, Times, Serif; color: #555759; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">Anika
                           customer service:</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">1-888-721-1600</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #555759"><font style="font-size: 8pt">customerservice@anikatherapeutics.com</font></p>



</td></tr>
</table>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"><img src="logo.jpg" alt="" style="height: 39; width: 200" >&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="color: #2F2F2F"><u>Benefits</u>: You will be eligible
to participate in the Anika employee benefit programs upon commencement of employment</font> to the same extent as, and subject
to the same terms, conditions and limitations applicable to, other employees of the Company of similar rank and tenure<font style="color: #2F2F2F">.
This program currently includes comprehensive medical and dental benefits, life and disability insurance, supplemental disability
insurance, and a Section 125 Plan. You will be eligible to participate in our 401(k) Savings and Investment Plan at the first enrollment
date (first day of each month) following your date of hire. Under the current terms, the 401(k) plan entitles you to contribute
up to the maximum limit established by the IRS. Furthermore, under the current 401(k) plan, the Company will match 140% of your
contribution up to 5% of your eligible compensation or to the limit specified by the Internal Revenue Code. There is a four-year
vesting schedule. The amount of the Company match is subject to the discretion of the Company</font><font style="color: #4F4F4F">.
</font><font style="color: #2F2F2F">Your participation in the benefit plans will be governed by and subject to the plan terms as
described in the official documents and Summary Plan Descriptions. </font>Please note that the Company may alter, add to, modify
or delete its benefits programs at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="color: #2F2F2F"><u>Vacation</u>: </font>You are
eligible for vacation days, which will accrue in accordance with Anika&rsquo;s vacation policy, as may be modified from time to
time, in the sole discretion of the Company. Subject to the current terms of accrual and use set forth in Anika&rsquo;s policies,
you <font style="color: #2F2F2F">will accrue four weeks of vacation during your first year of employment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2F2F2F"><u>Termination of Employment:</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="color: #2F2F2F">1)</font></td><td><font style="color: #2F2F2F">Resignation or Termination for Cause: Notwithstanding the at-will relationship between you and
the </font>Company, if you voluntarily resign employment or are terminated for &ldquo;Cause&rdquo; at any time, all compensation
and benefits payable to you under this Agreement shall terminate on the date of termination of your employment.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">For purposes of this offer letter, &ldquo;Cause&rdquo;
shall mean any one or more of the following: (i) conduct constituting a material act of willful misconduct or gross negligence
in connection with the performance of your duties, including, without limitation, misappropriation of funds or property of the
Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for
personal purposes; (ii) the commission of any felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, or
any conduct that would reasonably be expected to result in material injury to the Company or any of its subsidiaries and affiliates
if you were retained in your position; (iii) continued, willful and deliberate non-performance your duties hereunder (other than
by reason of physical or mental illness, incapacity or disability) which has continued for more than 30 days following written
notice of such non-performance from the Chief Executive Officer; (iv) a breach of any of the provisions contained in the <i>Confidentiality
and Proprietary Rights Agreement</i>; (v) a violation by of the Company&rsquo;s employment policies which has continued following
written notice of such violation from the Board, or (vi) willful failure to cooperate with a bona fide internal investigation or
an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful
destruction or failure to preserve documents or other materials known to be relevant to such investigation or the willful inducement
of others to fail to cooperate or to produce documents or other materials in connection with such investigation. For purposes of
clauses (i), (iii) and (vi) hereof, no act, or failure to act, on the Executive&rsquo;s part shall be deemed &ldquo;willful&rdquo;
unless done, or omitted to be done, by you without reasonable belief that your acts or failure to act, was in the best interest
of the Company and its subsidiaries and affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 50%"><p style="color: #19559A; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">ANIKA
                           THERAPEUTICS, INC.</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">32 Wiggins Avenue</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Bedford, MA 01730</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">anikatherapeutics.com</font></p>


</td>
    <td style="width: 50%"><p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">&#160;</font></p>
                           <p style="font: 10pt Times New Roman, Times, Serif; color: #555759; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">Anika
                           customer service:</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">1-888-721-1600</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #555759"><font style="font-size: 8pt">customerservice@anikatherapeutics.com</font></p>



</td></tr>
</table>
<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"><img src="logo.jpg" alt="" style="height: 39; width: 200" >&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="color: #2F2F2F">2)</font></td><td>Termination Without Cause: Termination of your employment without Cause or in conjunction with a Change in Control shall be
regulated by the <i>Executive Retention Agreement </i>being provided with this Offer Letter, which shall be executed and become
effective upon your start date.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="color: #2F2F2F"><u>Confidentiality and Proprietary
Rights Agreement</u>: You understand that as a condition of your employment, you will be required to execute Anika's <i>Confidentiality
and Proprietary Rights Agreement</i></font><font style="color: #4F4F4F">, </font><font style="color: #2F2F2F">a copy of which is
enclosed. You further understand that the Anika <i>Confidentiality and Proprietary Rights Agreement</i> contains conditions that
will survive the termination of your employment, regardless of the reason for that termination.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="color: #2F2F2F"><u>Arbitration</u>: Except for
any request by the Company or by you for temporary, preliminary or permanent injunctive relief from a court of competent jurisdiction
to enforce or enjoin any portion of the <i>Confidentiality and Proprietary Rights Agreement</i> (which right shall remain in full
force and effect following the termination of your employment with the Company), in the event of any dispute, controversy or claim
arising out of or relating to this offer letter, your employment with the Company, or the termination of your employment including
but not limited to, any claims arising out of M.G.L. ch.151B, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities
Act, the Age Discrimination in Employment Act, the Family and Medical Leave Act, the Small Necessities Leave Act, the Massachusetts
Civil Rights Act (M.G.L. ch. 12), or any other federal, state or local statute, regulation or ordinance that provides protection
against employment discrimination, harassment or retaliation; any claims under the Fair Labor Standards Act or M.G.L. ch. 149 or
any other federal, state or local statute, regulation or ordinance that provides protection against wage and hour and/or wage payment
violations; any claims under the federal or state equal pay act; any tort and/or privacy claims, including those under the Massachusetts
Privacy Statute (M.G.L. ch. 214), that dispute, controversy or claim shall, to the fullest extent permitted by law, be settled
by binding arbitration before an arbitrator experienced in employment law. Said arbitration will be conducted in accordance with
the Employment Dispute Resolution Rules and Mediation Procedures of the American Arbitration Association (&ldquo;AAA&rdquo;) in
Boston, Massachusetts, including, but not limited to</font><font style="color: #4F4F4F">, </font><font style="color: #2F2F2F">the
rules and procedures applicable to the selection of arbitrators (or alternatively, in any other forum or in any other form agreed
upon by the parties). In the event that any person or entity other than you or Anika may be a party with regard to any such controversy
or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity's agreement. Judgment
upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This provision shall be specifically
enforceable. Arbitration as provided in this section shall be the exclusive, final and binding remedy for any such dispute and
will be used instead of any court action, which is hereby expressly waived. The Federal Arbitration Act shall govern the interpretation
and enforcement of such arbitration proceeding. The arbitrator shall apply the substantive law (and the law of remedies, if applicable)
of the Commonwealth of Massachusetts, or federal law, if Massachusetts law is preempted. You acknowledge and understand that by
agreeing to arbitrate, you are waiving any right to bring an action against the company in a court of law, either state or federal,
and the right to a trial by jury, except as otherwise expressively set forth in this agreement. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 50%"><p style="color: #19559A; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">ANIKA
                           THERAPEUTICS, INC.</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">32 Wiggins Avenue</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Bedford, MA 01730</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">anikatherapeutics.com</font></p>


</td>
    <td style="width: 50%"><p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">&#160;</font></p>
                           <p style="font: 10pt Times New Roman, Times, Serif; color: #555759; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">Anika
                           customer service:</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">1-888-721-1600</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #555759"><font style="font-size: 8pt">customerservice@anikatherapeutics.com</font></p>



</td></tr>
</table>
<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"><img src="logo.jpg" alt="" style="height: 39; width: 200" >&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="color: #2F2F2F"><u>Background Check and Drug Testing</u>:
</font><font style="color: #2E2E2E">You understand and agree that all employees are subject to a background check, including verification
of education, and drug testing. You will be sent a link to the on-line information and release</font><font style="color: #4F4F4F">.
</font><font style="color: #2E2E2E">This offer is conditioned on the background check and drug testing results being satisfactory
to the Company. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Reference Checks</u>: You also understand and agree this
offer is contingent upon the completion of satisfactory reference checks in the sole discretion of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>At-Will Employment</u>: You, like everyone else at Anika,
will be an at-will employee. This means that, if you accept this offer, both you and the Company will retain the right to terminate
your employment at any time, with or without notice or cause. In accepting this offer, you give us assurance that you have not
relied on any agreement or representation, express or implied, with respect to your employment that is not set forth expressly
in this letter. The terms of your employment will be interpreted in accordance with and governed by the laws of the Commonwealth
of Massachusetts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Representation Regarding Other Agreements</u>: Finally, this
offer is conditioned on your representation that you are not subject to any confidentiality or non-competition agreement, court
order, or any similar type of restriction that would affect your ability to devote full time and attention to your work at Anika.
You further agree that you will not disclose to, or use on behalf of, the Company any proprietary information of a third party
without that party's consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Eligibility to Work</u>. Your employment with the Company
is conditioned on your eligibility to work in the United States and on your providing to the Company proof of identification and
authorization to work in the United States, in accordance with the Immigration and Control Act of 1986. Should you choose to accept
this offer, as required by law, we must verify your employment eligibility on Form I-9 the day you begin your employment, so you
will be asked to provide documentation that establishes your identity and authorizes you to work in the United States. Furthermore,
if applicable, you must always maintain your visa status throughout your tenure with the Company, as it is Company policy to comply
with all immigration laws and regulations. Please let the Company know if you have any questions concerning your visa status.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Company Policies and Procedures</u>. You will be required
to abide by Company policies and procedures, as in effect from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the terms of this offer are acceptable, please indicate your
acceptance by signing both copies of this letter, the Anika <i>Confidentiality and Proprietary Rights Agreement</i>, and the <i>Executive
Retention Agreement</i>, and return one copy of each back to me. This offer is valid until July 31.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 50%"><p style="color: #19559A; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">ANIKA
                           THERAPEUTICS, INC.</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">32 Wiggins Avenue</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Bedford, MA 01730</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">anikatherapeutics.com</font></p>


</td>
    <td style="width: 50%"><p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">&#160;</font></p>
                           <p style="font: 10pt Times New Roman, Times, Serif; color: #555759; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">Anika
                           customer service:</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">1-888-721-1600</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #555759"><font style="font-size: 8pt">customerservice@anikatherapeutics.com</font></p>



</td></tr>
</table>

<!-- Field: Page; Sequence: 4 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"><img src="logo.jpg" alt="" style="height: 39; width: 200" >&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>/s/ Thomas Finnerty</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thomas Finnerty</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President Human Resources</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Agreed and accepted:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="width: 51%; text-align: left"><u>/s/ Michael Levitz</u></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 47%; text-align: left"><u>July 29, 2020</u></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Michael Levitz</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: left">Date</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Enclosures:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Executive Retention Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2F2F2F"><i>Confidentiality and Proprietary Rights Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2F2F2F"><i>Job Description</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 50%"><p style="color: #19559A; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">ANIKA
                           THERAPEUTICS, INC.</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">32 Wiggins Avenue</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Bedford, MA 01730</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">anikatherapeutics.com</font></p>


</td>
    <td style="width: 50%"><p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">&#160;</font></p>
                           <p style="font: 10pt Times New Roman, Times, Serif; color: #555759; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">Anika
                           customer service:</font></p>

<p style="color: #555759; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-size: 8pt">1-888-721-1600</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #555759"><font style="font-size: 8pt">customerservice@anikatherapeutics.com</font></p>



</td></tr>
</table>
<p style="margin: 0" ></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="font-size: 1pt; border-top: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">

</p>
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Anika Appoints Michael Levitz as Chief Financial Officer</strong></font></p><p style="text-align: center;"><strong>Seasoned financial executive brings broad medical device industry experience and track record of value creation</strong></p><p>
 <p align="left">BEDFORD, Mass., Aug.  05, 2020  (GLOBE NEWSWIRE) -- <u>Anika Therapeutics, Inc.</u> (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced the appointment of Michael Levitz as Executive Vice President, Chief Financial Officer and Treasurer, starting August 10, 2020. Mr. Levitz brings over 20 years of public company financial experience to Anika and has helped deliver significant increases in enterprise value and operating performance at several medical device companies. He succeeds Sylvia Cheung, who will continue with the Company in an advisory capacity for a period following the succession effective date to assist with a smooth transition.<br ></p>  <p>&#8220;Anika is delighted to welcome Mike to our leadership team during this pivotal time of momentum and growth for the Company,&#8221; said Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Anika. &#8220;His extensive experience building, developing, and retaining high-performing teams during significant periods of growth and transformation will be invaluable as we continue to integrate the acquisitions of Parcus Medical and Arthrosurface, leverage our expanded global commercial reach, and advance our strategic growth plan.&#8221;</p>  <p>&#8220;Anika is at an exciting stage of its corporate evolution, with a strong financial foundation and a robust and growing early intervention orthopedic product portfolio and pipeline,&#8221; said Mr. Levitz. &#8220;I look forward to contributing to the Company&#8217;s culture of financial discipline and investment in innovation to accelerate growth and value creation for shareholders.&#8221;</p>  <p>Prior to joining Anika, Mr. Levitz served as Senior Vice President, Chief Financial Officer and Treasurer of Insulet Corporation, a global innovative medical device and drug delivery company. Prior to Insulet, from 2009 to 2015 he was the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation, a global provider of medical guidance, diagnostic imaging and threat detection equipment. Previously, during his seven years with Hologic, Inc. and Cytyc Corporation (which merged with Hologic in October 2007), Mr. Levitz served in various capacities including Vice President and Corporate Controller. Mr. Levitz began his career in the high technology audit practice at Arthur Andersen. Mr. Levitz earned his Bachelor of Arts in Business Economics, with emphasis in Accounting, from the University of California Santa Barbara and is a certified public accountant. In 2011, he was a finalist for the Boston Business Journal's Chief Financial Officer of the Year award.</p>  <p><strong>About Anika Therapeutics, Inc.</strong></p>  <p>Anika Therapeutics, Inc.&#160;(NASDAQ: ANIK), is a global, integrated joint preservation, restoration and regenerative solutions company based in Bedford, Massachusetts. Anika is committed to delivering products along the orthopedic early intervention continuum of care to improve the lives of patients, with a focus on osteoarthritis pain management, sports medicine and joint preservation, restoration and regeneration. The Company has close to three decades of global expertise commercializing innovative products across the orthopedic early intervention continuum of care. For more information about Anika, please visit www.anikatherapeutics.com.</p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:50%; width:50%; min-width:50%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><br >For Investor Inquiries:<br > Anika Therapeutics, Inc.<br > Kristen Galfetti, 781-457-9000<br > Executive Director, Investor Relations <br ><u>investorrelations@anikatherapeutics.com</u> <br > &#160;</td><td style="max-width:50%; width:50%; min-width:50%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; ">For Media Inquiries:<br > W2O Group<br > Rachel Girard, 617-379-6760 &#160;<br ><u>r</u><u>girard</u><u>@w2ogroup.com</u></td></tr></table></p><p ></p></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_X0K917AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  ,EJ@   G
M$  R6J   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,C Z,#@Z
M,#4@,3,Z-3$Z,3D      Z !  ,    !__\  * "  0    !    R* #  0
M   !    )P         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   FC
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 'P"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M,208[:\7T?_9_^T/>E!H;W1O<VAO<" S+C  .$))300E       0
M             #A"24T#[0      $ %*     0 ! 4H    !  $X0DE-!"8
M      X             /X   #A"24T$#0      !    !XX0DE-!!D
M  0    >.$))30/S       )           ! #A"24T$"@       0  .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #/0    8              "<   #(    ! !L &\ 9P!O
M     0                         !              #(    )P
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    )P    !2
M9VAT;&]N9P   ,@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   "<     4F=H=&QO;F<   #(
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M248  0(  $@ 2   _^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1
M"  ? * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P !
M @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"
M! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M0P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%
M!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C
M<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#I?KE]
M=+.EVGIG3-ISMH-USAN;2'"6-:S_  F0]OZ3W_HZV?OKS[(S>HY]H^TWWYEM
MC@UC'.=82YQ]M=-(]NYSOH5U5J.5;?E]0O>]KGY>3>\NJ:";#:YYFEM3?=O:
M[]%L5ST;L*YO3<)X=UG(<,>Z^MP(H=8?2^P8MS?\/[O\HYE?T/Z)1_AWK6QX
MH8H@ #CJS+\S_<<^<Y9)$DD0!JOY?I/<_4SZJ]2Z:&YO4<JYEA!V=.9:XTM!
M$3D-EU=MW_%_HZO^%6MT+ZS8'6[,NG']EV':]A83.^L.=75E5.TW57;/^M_]
MM^HW639T?ZJY+<+>7X>)Z=+A)<-K/299I_H_YQ<']4L;(Z/UGIV7F;\5N63C
M8^*1^FN;9[/5LJ<6.HPZGM9;ZMOZ2VST_2J_/5,1]Z.3)(^K:%?U?5\K9XO;
M,(1'I_2_WWU1))0ONJQZ;,B]PKJI:7V//#6M&Y[C_5:JK.S27F.5E?63JM&9
M]<,.^['QL2]OV3%#GAIIJ_G;7TM=Z=GI_P#:G_2?K?\ H:UW_0^KX_6>F4=0
MH]HM$65S)98WVVU._J/4N3"8 &P=>&5?H3_=8X9!(U5=1?Z4>[?25;JA<WIF
M6YI+7"BPAP,$'8[4$+S;ZM_6OKG1L2G*S6VYW1KWFLO>[>]EC8]1M5UCMS7N
MG>W'R'>G?_VGL_G$L>"62,C$BP:X?WO)4\H@0#>O7L^I)+"ZSU7%S_JEGY_3
M<C?6<>PLMK):YK@/H_FV56L_=^FE]1K;;OJK@V76/ML<+-S['%[C^EM'N>\N
M<FG&1 S.E2X.%=QCB$>XXK=U)<A_C.R,C'Z)COQ[K*'G)@NJ>ZLD>E>=NZLM
M\%U& 2<''+B234PDDR2=HY*1A4(SOYB17]U0G<C'L ?M3I+@_KGGW8?UOZ0X
MY-E&(P569 ;8YM>QMSO4=;6QVQ_L_DHN1USZP?6NY^%]6V.P>FM=LOZI9+7&
M/I-J_/K_ *C/UC^;]2S#4@Y>7#&5@1D.(R.D8+/>%F-'B!JOWGMTEF=$Z%1T
MBG:+[\O(> +<C(L?8YT=F,>YS*:_Y%?_ %SU%I/>RMCGV.#&,!<YSC  &KG.
M<5"0+H&QWV9!=:Z+I+S3-R>O?6$=3^L?3<F['P^FN8W!IK<YHL;6?5OM=6',
M:Y[&?K#_ %*[/4_HO^"7<?5SK=77.DU9[(;8?9D5CAEK?YQG]77U*_\ @GL4
MF3 81!L'6I#]R7S45D,@D:JNL?ZP?__0V/KUUK&Z=DV872J*\?JN37NR^HL8
MUMK*WR!75<T>IZ]VW^=_P-?_  WI^E+ZM?L;K?7L7+Z9TW]GT]'QCZHAH#KK
M?T6.R*Y]1M%;,IS,A_Z5^]7?KKT3HW4[&O=U#'P.K55PSU[&M%E9+MC+V.=Z
MFS?O]*]G_"?SBP?JWG]7Z%BY^/@]-'4LJVQKAD8UK,BIHV[&>M]C=9=M]KK*
MZ_T/J;_\$KL.&>'A@?UM<-$U\WIE_>CPM:7%')<OYO?;L]E]9OK/B= Q=SHN
MS+0?LV,#!<?])9_HZ&?GO7!?5=F=UWZWT9F6\W65..5DV\!K:P6T5L;^97ZS
MV-KK_KJD_IO6.H]2L=U.^K&RK"'7W9]U=+F@_0_52_[1Z>W^9K90RI>C?5/I
MW0^FX;\;I>55G7^UV;D5O8][G$'T][:G/]&KZ?V>G_T9ZMB4O;P8Y1!$LLAP
MFOT5#CRS!(X<<=1_6=U<;]=LS+ZEF8WU4Z:UQLR7-?FV[3L:P>]E;W_N^W[1
M=_Q=57^'79)*KCGP2XJLC;^]TDSSCQ"KJ]_)XZCZH_6O&QF8F/U]M>-6W8RD
M8[=H;^[[B[=_:6=]7_MOU/\ K&>C9I=;T_/#/3O8UWIBP_HZ;X_2>EN<W[+D
M>[_06_S:]"24GWB1$A("0D-:$8:_O7%;[(L&)(,=M>+3LU>JS^S,P#4^A;H-
M?S'+F?\ %SBUW_52S&RZ=]5E]K;*K6Z.:17])E@78)*,9*@85N1*_P"ZN,+D
M)=@17F^==?\ JEU/H3,O)Z$]]O2\NLUYF)]-[:SI]!VYV175_@[OZ9C?\+7Z
MBZ;ZAM<WZIX <"T@6Z.!!_G;>SEOI)\\\IXQ"0LV#Q]37I]2V.(1GQ#M7#T^
MCQO^-)CW]"Q@QKGG[5PT%Q_F<C]T%=7T_P#H&-.GZ)G_ %+4=),.2X1A7RDF
M_P"\N$*F97N /L>"^N='K_73HK'U&VE_HLM!87,+77D/99H6;=OTMR)U#ZK]
M9^KN2[JGU4M>^CZ5_372^6C7:QA=^LL_=9_3*_\  76?S:[E)2#F) 1B .&(
MX91.L9_19[(N1O61L$;Q<'ZN?6W#ZV!194_#SP"78]C7 . ^D_'M<UC;6_R/
MYYG^C6?]>NHY=_V?ZM=-:Y^5U$M&0YH=M;43]!]C6[6>KM<ZW_NM5;_I:UUR
M28)QC/C$-!J(DWZEQB3'A,M^M='CL3ZH_6O!H9BX77VT8]4^G4W'; DE[OI.
M=])[OSEE]*JSOJ5]9&8F43?T[J+6BR^NLA@=.UENWW^D['M=Z=OO_H]WJ?F+
MT5)/',2]0D!(3'JH1A_A<45OLC0Q)!CMKQ?1_]D .$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P R     0 X0DE-! 8
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M .<9O_+.:%_P,_\ U5S6?Z(-?_JTG/\ Y%T7^I!\E_D[_P XV_GM_P X\?\
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@Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
